STAT

Opinion: We need more answers about immunotherapy for the elderly

People older than 65 make up more than half of cancer patients. We need to learn how well immunotherapy works for them.
A cancer patient receives infusions of the immunotherapy Keytruda in New York City.

An old idea — using the body’s immune system to fight cancer cells, first proposed more than a century ago — has become one of the most promising approaches to treating cancer today. Immunotherapy is effective against a variety of cancers, with sometimes spectacular results. But I worry about how effective it is in people over age 65, who make up half of cancer patients.

We know that immunotherapy is by older individuals. But how well they. It causes the immune system to change and become less effective over time. Since immunotherapy involves harnessing the immune system to fight cancer, there are questions about how well it works in patients whose immune systems are changing.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.

Related Books & Audiobooks